Trial Profile

A phase I/II clinical trial of REN 001

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REN 001 Rocket Pharmaceuticals (Primary)
Indications Dilated cardiomyopathy
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Dec 2022 According to a Renovacor media release, Renovacor has been acquired and merged into Rocket Pharmaceuticals.
24 Mar 2022 According to a Renovacor media release, company is working diligently to submit an IND application in the second half of this year and initiate this trial thereafter.
06 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com